Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
19,180,997
-
Shares change
-
-1,589,935
-
Total reported value, excl. options
-
$2,423,578,574
-
Value change
-
-$145,246,067
-
Put/Call ratio
-
94.7%
-
Number of buys
-
85
-
Number of sells
-
-72
-
Price
-
$126.36
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q3 2018
225 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q3 2018.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19,180,997 shares
.
Largest 10 shareholders include FMR LLC (4,434,702 shares), BlackRock Inc. (2,110,651 shares), Vanguard Group Inc (1,952,931 shares), JPMORGAN CHASE & CO (1,197,042 shares), FIRST TRUST ADVISORS LP (1,092,319 shares), STATE STREET CORP (1,010,966 shares), BB BIOTECH AG (545,719 shares), DEUTSCHE BANK AG\ (483,169 shares), ALTRINSIC GLOBAL ADVISORS LLC (312,627 shares), and NORGES BANK (282,045 shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.